• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Tracking Clonal Evolution of EGFR-Mutated Non-Small Cell Lung Cancer Through Liquid Biopsy: Management of C797S Acquired Mutation.

作者信息

Russo Alessandro, Scilla Katherine A, Mehra Ranee, Gittens Allison, McCusker Michael G, de Miguel-Perez Diego, Gomez Jorge E, Peleg Ariel, Del Re Marzia, Rolfo Christian D

机构信息

Marlene and Stewart Greenebaum Comprehensive Cancer Center, Division of Hematology/Oncology, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD; Department of Onco-Hematology, Papardo Hospital, Messina, Italy.

Marlene and Stewart Greenebaum Comprehensive Cancer Center, Division of Hematology/Oncology, Department of Medicine, University of Maryland School of Medicine, Baltimore, MD.

出版信息

Clin Lung Cancer. 2023 Nov;24(7):660-665. doi: 10.1016/j.cllc.2023.07.003. Epub 2023 Jul 19.

DOI:10.1016/j.cllc.2023.07.003
PMID:37487787
Abstract
摘要

相似文献

1
Tracking Clonal Evolution of EGFR-Mutated Non-Small Cell Lung Cancer Through Liquid Biopsy: Management of C797S Acquired Mutation.通过液体活检追踪表皮生长因子受体（EGFR）突变的非小细胞肺癌的克隆进化：C797S获得性突变的管理
Clin Lung Cancer. 2023 Nov;24(7):660-665. doi: 10.1016/j.cllc.2023.07.003. Epub 2023 Jul 19.
2
Sequential liquid biopsies reveal dynamic alterations of EGFR driver mutations and indicate EGFR amplification as a new mechanism of resistance to osimertinib in NSCLC.连续液体活检揭示了EGFR驱动基因突变的动态变化，并表明EGFR扩增是NSCLC中对奥希替尼耐药的一种新机制。
Lung Cancer. 2017 Jun;108:238-241. doi: 10.1016/j.lungcan.2017.04.004. Epub 2017 Apr 10.
3
EGFR-Mutated Lung Cancers Resistant to Osimertinib through EGFR C797S Respond to First-Generation Reversible EGFR Inhibitors but Eventually Acquire EGFR T790M/C797S in Preclinical Models and Clinical Samples.奥希替尼耐药的 EGFR 突变型肺癌对第一代可逆性 EGFR 抑制剂敏感，但在临床前模型和临床样本中最终会获得 EGFR T790M/C797S 耐药突变。
J Thorac Oncol. 2019 Nov;14(11):1995-2002. doi: 10.1016/j.jtho.2019.07.016. Epub 2019 Aug 1.
4
Identifying Resistance Mechanisms to Osimertinib via Blood Biopsy.通过血液活检确定对奥希替尼的耐药机制。
Clin Lung Cancer. 2019 Nov;20(6):e597-e600. doi: 10.1016/j.cllc.2019.08.002. Epub 2019 Aug 26.
5
Challenging BRAF/EGFR co-inhibition in NSCLC using sequential liquid biopsies.使用连续液体活检来挑战 NSCLC 中的 BRAF/EGFR 共抑制。
Lung Cancer. 2019 Jul;133:45-47. doi: 10.1016/j.lungcan.2019.05.003. Epub 2019 May 4.
6
Resistance mechanisms to osimertinib in EGFR-mutated advanced non-small-cell lung cancer: A multicentric retrospective French study.奥希替尼治疗表皮生长因子受体突变型晚期非小细胞肺癌的耐药机制：一项多中心回顾性法国研究。
Lung Cancer. 2019 Nov;137:149-156. doi: 10.1016/j.lungcan.2019.09.019. Epub 2019 Sep 28.
7
Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non-Small Cell Lung Cancer Patients.探索非小细胞肺癌患者对第三代 EGFR 酪氨酸激酶抑制剂奥希替尼产生新耐药机制。
Clin Cancer Res. 2018 Jul 1;24(13):3097-3107. doi: 10.1158/1078-0432.CCR-17-2310. Epub 2018 Mar 5.
8
Efficacy of immunotherapy targeting the neoantigen derived from epidermal growth factor receptor T790M/C797S mutation in non-small cell lung cancer.针对表皮生长因子受体 T790M/C797S 突变的新型抗原的免疫疗法在非小细胞肺癌中的疗效。
Cancer Sci. 2020 Aug;111(8):2736-2746. doi: 10.1111/cas.14451. Epub 2020 Jun 18.
9
Acquired EGFR C797G Mutation Detected by Liquid Biopsy as Resistance Mechanism After Treatment With Osimertinib: A Case Report.液体活检检测到获得性 EGFR C797G 突变作为奥希替尼治疗后耐药机制：一例报告。
In Vivo. 2021 Sep-Oct;35(5):2941-2945. doi: 10.21873/invivo.12586.
10
The impact of osimertinib' line on clonal evolution in EGFRm NSCLC through NGS-based liquid biopsy and overcoming strategies for resistance.奥希替尼治疗线对表皮生长因子受体突变（EGFRm）非小细胞肺癌（NSCLC）克隆进化的影响：基于二代测序（NGS）的液体活检及耐药克服策略
Lung Cancer. 2021 Mar;153:126-133. doi: 10.1016/j.lungcan.2020.12.039. Epub 2021 Jan 14.

引用本文的文献

1
Combined Use of Gefitinib and Bevacizumab in Advanced Non-Small-Cell Lung Cancer with G719S/S768I Mutations and Acquired C797S Without T790M After Osimertinib: A Case Report and Literature Review.吉非替尼与贝伐单抗联合用于奥希替尼治疗后出现G719S/S768I突变和获得性C797S（无T790M）的晚期非小细胞肺癌：一例报告及文献复习
Curr Oncol. 2025 Mar 28;32(4):201. doi: 10.3390/curroncol32040201.
2
The growing field of liquid biopsy and its Snowball effect on reshaping cancer management.液体活检这一不断发展的领域及其对重塑癌症治疗的滚雪球效应。
J Liq Biopsy. 2025 Mar 27;8:100293. doi: 10.1016/j.jlb.2025.100293. eCollection 2025 Jun.
3
Application of an Integrated Single-Cell and Three-Dimensional Spheroid Culture Platform for Investigating Drug Resistance Heterogeneity and Epithelial-Mesenchymal Transition (EMT) in Lung Cancer Subclones.
一种整合的单细胞和三维球体培养平台在研究肺癌亚克隆中的耐药异质性和上皮-间质转化（EMT）中的应用
Int J Mol Sci. 2025 Feb 19;26(4):1766. doi: 10.3390/ijms26041766.
4
Transformation from acquired EGFR 19del/C797S to EGFR 19del/T790M in an advanced non-small cell lung cancer patient: a case report and literature review.一名晚期非小细胞肺癌患者从获得性表皮生长因子受体（EGFR）19 外显子缺失/C797S 转变为 EGFR 19 外显子缺失/T790M：病例报告及文献综述
Anticancer Drugs. 2025 Jul 1;36(6):513-517. doi: 10.1097/CAD.0000000000001707. Epub 2025 Feb 14.
5
Comprehensive liquid biopsy analysis for monitoring NSCLC patients under second-line osimertinib treatment.用于监测接受二线奥希替尼治疗的非小细胞肺癌患者的综合液体活检分析
Front Oncol. 2024 Oct 21;14:1435537. doi: 10.3389/fonc.2024.1435537. eCollection 2024.
6
Liquid and Tissue Biopsies for Lung Cancer: Algorithms and Perspectives.肺癌的液体活检与组织活检：算法与展望
Cancers (Basel). 2024 Sep 29;16(19):3340. doi: 10.3390/cancers16193340.